Balchem Co. (NASDAQ:BCPC) Shares Bought by Nebula Research & Development LLC

Nebula Research & Development LLC raised its holdings in Balchem Co. (NASDAQ:BCPC - Free Report) by 31.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,837 shares of the basic materials company's stock after purchasing an additional 2,328 shares during the quarter. Nebula Research & Development LLC's holdings in Balchem were worth $1,603,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Balchem by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,961,487 shares of the basic materials company's stock worth $645,703,000 after purchasing an additional 42,693 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Balchem by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 938,504 shares of the basic materials company's stock valued at $153,000,000 after buying an additional 9,600 shares during the period. Geneva Capital Management LLC grew its stake in shares of Balchem by 5.1% in the 4th quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company's stock valued at $133,615,000 after buying an additional 39,877 shares during the period. FMR LLC boosted its position in shares of Balchem by 16.0% during the fourth quarter. FMR LLC now owns 576,994 shares of the basic materials company's stock valued at $94,047,000 after buying an additional 79,499 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Balchem by 11.0% in the 4th quarter. JPMorgan Chase & Co. now owns 509,490 shares of the basic materials company's stock valued at $83,044,000 after buying an additional 50,504 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company's stock.

Balchem Price Performance

Shares of Balchem stock traded up $2.45 during trading on Monday, reaching $156.09. 145,439 shares of the stock traded hands, compared to its average volume of 132,747. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of 39.72, a P/E/G ratio of 4.41 and a beta of 0.75. Balchem Co. has a 52-week low of $137.69 and a 52-week high of $186.03. The business has a fifty day simple moving average of $163.94 and a two-hundred day simple moving average of $167.02.

Balchem (NASDAQ:BCPC - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The firm had revenue of $250.52 million during the quarter, compared to analysts' expectations of $245.70 million. During the same quarter in the previous year, the business earned $1.03 earnings per share. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts expect that Balchem Co. will post 4.64 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BCPC shares. HC Wainwright set a $180.00 price objective on Balchem and gave the stock a "buy" rating in a report on Monday. Sidoti raised shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. Finally, StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.